Funding
Hematris has raised €2 million from Aurelia Private Equity and the bank KfW to advance its Hematrix wound care product to market.
Hematrix is a biodegradable patch coated with blood-clotting components, which the company says will stop severe bleeding, even that caused by arterial injury and external bleeding caused by surgical intervention, in just a few minutes.
Stefan Bertsch, founder of Hematris, said there is no competition for Hematrix anywhere in the world. “Working together with our new investors, we have the potential to position ourselves in a lucrative and growing market and develop new applications in the field of external blood clotting.”
Munich-based Hematris received seed funding from High-Tech Gründerfonds and with Berliner Peppermint Holding to develop the preclinical prototype. Following clinical studies Hematris has now received the CE Certification to launch the product.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
